Compare Asuransi Harta Aman Pratama Tbk (AHAP) vs Brigit Biofarmaka Teknologi Tbk. (OBAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asuransi Harta Aman Pratama Tbk vs Brigit Biofarmaka Teknologi Tbk. — how do they compare? Asuransi Harta Aman Pratama Tbk trades at Rp99 (market cap 455.7B, 59.01M 24h volume), while Brigit Biofarmaka Teknologi Tbk. trades at Rp236 (market cap 164.65B, 62.5K 24h volume). The key difference: Asuransi Harta Aman Pratama Tbk is far larger — about 2.8× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Asuransi Harta Aman Pratama Tbk is more actively traded (59.01M versus 62.5K). Which is the better fit depends on your goals.
| AHAP | OBAT | |
|---|---|---|
Market Cap | 455.7B | 164.65B |
Volume | 59.01M | 62.5K |
Lot | 590.1K | 625 |
Turnover | 5.83B | 15.03M |
Average Price | 98.73 | 240.55 |
Value | 5.83B | 15.03M |
Indicative Equilibrium Price | 99 | 238 |
Indicative Equilibrium Volume | 8.59K | 100 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asuransi Harta Aman Pratama Tbk
PT Asuransi Harta Aman Pratama Tbk was established on May 28, 1982 and was approved by the Minister of Justice under decree No. C2-1325.HT.01.01.tH.82 dated September 21, 1982. Then on February 11, 1983 the Company was approved by the Ministry of Finance of The Republic of Indonesia No. 633/MD/1983. The Company’s founders sold their share of stock to local and foreign investors and now its ownership of the stocks spread almost equally to a lot of people and the biggest shareholders is 12%; thus, there are no single majority shareholders in the Company.
Read more on AHAP →About Brigit Biofarmaka Teknologi Tbk.
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →
